MedTrace Logo

Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis

NCT04617028 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 105

Last updated 2023-11-13

No results posted yet for this study

Summary

This study is to determine the efficacy of Jaktinib versus Hydroxycarbamid in participants with Intermediate-2 or High-risk myelofibrosis

Conditions

Interventions

DRUG

Jaktinib

Jaktinib Hydrochloride Tablets administered orally twice daily

DRUG

Placebo to match Hydroxycarbamide

Placebo to match Hydroxycarbamide Tablets administered orally twice daily

DRUG

Hydroxycarbamide Tablets

Hydroxycarbamide Tablets administered orally twice daily

DRUG

Placebo to match Jaktinib

Placebo to match Jaktinib Tablets administered orally twice daily

Sponsors & Collaborators

  • Suzhou Zelgen Biopharmaceuticals Co.,Ltd

    lead INDUSTRY

Principal Investigators

  • Jie Jin, PhD · The First Affiliated Hospital of Medical School of Zhejiang University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-05
Primary Completion
2023-10-18
Completion
2023-10-18

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04617028 on ClinicalTrials.gov